Edge Therapeutics, Inc. - Product Pipeline Review - 2013

Date: December 31, 2013
Pages: 26
Price:
US$ 1,500.00 US$ 1,350.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: EDC84AA3BF5EN
Leaflet:

Download PDF Leaflet

Global Market Direct’s pharmaceuticals report, “Edge Therapeutics, Inc. - Product Pipeline Review - 2013” provides data on the Edge Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Edge Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Edge Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope
  • Edge Therapeutics, Inc. - Brief Edge Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Edge Therapeutics, Inc. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Edge Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
  • Recent updates of the Edge Therapeutics, Inc.’s pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Evaluate Edge Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
  • Assess the growth potential of Edge Therapeutics, Inc. in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Edge Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Edge Therapeutics, Inc..
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Edge Therapeutics, Inc. and identify potential opportunities in those areas.
Edge Therapeutics, Inc. Snapshot
Edge Therapeutics, Inc. Overview
Key Information
Key Facts
Edge Therapeutics, Inc. - Research and Development Overview
Key Therapeutic Areas
Edge Therapeutics, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Edge Therapeutics, Inc. - Pipeline Products Glance
Edge Therapeutics, Inc. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Edge Therapeutics, Inc. - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Edge Therapeutics, Inc. - Drug Profiles
EG-1962
Product Description
Mechanism of Action
R&D Progress
aminocaproic acid SR
Product Description
Mechanism of Action
R&D Progress
EG-1960
Product Description
Mechanism of Action
R&D Progress
Edge Therapeutics, Inc. - Pipeline Analysis
Edge Therapeutics, Inc. - Pipeline Products by Therapeutic Class
Edge Therapeutics, Inc. - Pipeline Products by Target
Edge Therapeutics, Inc. - Pipeline Products by Route of Administration
Edge Therapeutics, Inc. - Pipeline Products by Molecule Type
Edge Therapeutics, Inc. - Pipeline Products by Mechanism of Action
Edge Therapeutics, Inc. - Recent Pipeline Updates
Edge Therapeutics, Inc. - Dormant Projects
Edge Therapeutics, Inc. - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Edge Therapeutics, Inc., Key Information
Edge Therapeutics, Inc., Key Facts
Edge Therapeutics, Inc. - Pipeline by Indication, 2013
Edge Therapeutics, Inc. - Pipeline by Stage of Development, 2013
Edge Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013
Edge Therapeutics, Inc. - Phase II, 2013
Edge Therapeutics, Inc. - Phase I, 2013
Edge Therapeutics, Inc. - Preclinical, 2013
Edge Therapeutics, Inc. - Discovery, 2013
Edge Therapeutics, Inc. - Pipeline by Therapeutic Class, 2013
Edge Therapeutics, Inc. - Pipeline by Target, 2013
Edge Therapeutics, Inc. - Pipeline by Route of Administration, 2013
Edge Therapeutics, Inc. - Pipeline by Molecule Type, 2013
Edge Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2013
Edge Therapeutics, Inc. - Recent Pipeline Updates, 2013
Edge Therapeutics, Inc. - Dormant Developmental Projects,2013

LIST OF FIGURES

Edge Therapeutics, Inc. - Pipeline by Top 10 Indication, 2013
Edge Therapeutics, Inc. - Pipeline by Stage of Development, 2013
Edge Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013
Edge Therapeutics, Inc. - Pipeline by Top 10 Therapeutic Class, 2013
Edge Therapeutics, Inc. - Pipeline by Top 10 Target, 2013
Edge Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2013
Edge Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2013
Edge Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2013

Ask Your Question

Edge Therapeutics, Inc. - Product Pipeline Review - 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: